Walmart is the latest US retail pharmacy giant to announce its intention of disrupting the clinical trials category, with the launch of a new institute that pledges to increase and diversify community ...

In the latest of a flurry of announcements ahead of the holiday period, CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and ...

In the latest of a flurry of announcements ahead of the holiday period, CMS has revealed a new, voluntary access programme ...

The French pharma major has started a $15.50 per share cash tender offer for Emeryville, California-based Dynavax, which ...

In labs, water consumption and single-use plastics like pipette tips can contribute to environmental impact. Lab equipment ...

Months of uncertainty have come to a close. The BIOSECURE Act, now part of the National Defense Authorization Act (NDAA), will put in motion US government-wide restrictions on ‘biotechnology companies ...

Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb's ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is GSK's depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an ...

Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel drug targets and therapeutics for Parkinson's disease. The partnership ...

The FDA has added a warning label to bluebird bio's Skysona, after launching an investigation into cases of blood cancer in patients treated with the ex vivo gene therapy last November. Skysona ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...

The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s complex studies. AI is rapidly emerging as an essential strategic tool to ...